Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Recommendation of “Buy” from Analysts

Bicara Therapeutics Inc. (NASDAQ:BCAX) has been given an average recommendation of “Buy” by the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $43.00.

Several brokerages have issued reports on BCAX. RODMAN&RENSHAW upgraded shares of Bicara Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 5th. TD Cowen began coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set a “buy” rating for the company. Stifel Nicolaus began coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set a “buy” rating and a $47.00 price objective for the company. Rodman & Renshaw began coverage on shares of Bicara Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating and a $48.00 price objective for the company. Finally, Morgan Stanley began coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set an “overweight” rating and a $35.00 price objective for the company.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of BCAX. First Turn Management LLC bought a new position in Bicara Therapeutics during the third quarter worth $14,324,000. The Manufacturers Life Insurance Company bought a new position in Bicara Therapeutics during the third quarter worth $582,000. FMR LLC bought a new position in shares of Bicara Therapeutics in the third quarter valued at $57,913,000. Walleye Capital LLC bought a new position in shares of Bicara Therapeutics in the third quarter valued at $809,000. Finally, Vestal Point Capital LP bought a new position in shares of Bicara Therapeutics in the third quarter valued at $10,825,000.

Bicara Therapeutics Stock Up 1.9 %

Shares of NASDAQ BCAX opened at $12.11 on Monday. Bicara Therapeutics has a 52-week low of $11.56 and a 52-week high of $28.09. The company has a 50 day simple moving average of $18.11.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($1.14). As a group, research analysts expect that Bicara Therapeutics will post -2.59 earnings per share for the current year.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.